FUSION Blend (BPC-157 / MOTS-c / 5-Amino-1MQ / Tesamorelin): What It Is, Where to Get It Prescribed, and What It Costs

FUSION is not a single molecule. It is four independently studied agents — BPC-157, MOTS-c, 5-Amino-1MQ and tesamorelin — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Three are peptides; 5-Amino-1MQ is a small synthetic molecule, a quinolinium salt. Each has its own literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination and does not appear in any journal, so "does FUSION work" has to be broken into four questions: the combination itself has never been studied as a combination.

The rationale prescribers give is that body composition is governed by several systems at once — how fat cells store and release energy, how muscle handles glucose, how much growth hormone the pituitary releases, and whether the gut is inflamed — and each component is described as acting on a different one. FUSION is positioned as the metabolic blend for adults working on weight and energy without a GLP-1 medication, or alongside one.

Tesamorelin is 15 of the 45 mg in the vial, a third by mass, and the only component with an FDA-approved counterpart and human trials. Every 0.25 mL dose delivers 0.5 mg BPC-157, 0.5 mg MOTS-c, 0.5 mg 5-Amino-1MQ and 0.75 mg tesamorelin. The ratio is fixed by the formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not a weight-loss drug in the sense that semaglutide and tirzepatide are: none of its components is an appetite-regulating hormone analogue, and none has a randomised human trial for weight in the general population. It is not a stimulant or a thyroid agent, and not a steroid: tesamorelin prompts a pulse of your own growth hormone rather than supplying a hormone from outside. And it is not a substitute for a calorie deficit, resistance training and sleep, which is why prescribers frame it as support for those, not a replacement.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice. Animal work describes it activating the VEGFR2 receptor and downstream nitric-oxide signalling, the axis the body uses to grow new blood vessels into healing tissue. A 2011 paper in the Journal of Applied Physiology reported that it increased growth hormone receptor expression in cultured tendon fibroblasts and activated the FAK–paxillin pathway that governs cell migration. The receptor finding describes making those cells more responsive to growth hormone already present, not raising growth hormone; in FUSION, tesamorelin is the component that does that.

The largest body of BPC-157 research concerns the gastrointestinal lining — protection against NSAID- and alcohol-induced damage and effects in inflammatory bowel models, all in animals — which is why it sits in a metabolic blend at all. A fuller treatment is on the BPC-157 page.

MOTS-c is unusual because its gene sits inside the mitochondrial genome rather than the cell nucleus. A 2015 paper in Cell Metabolism described it as a mitochondrial-derived peptide acting on skeletal muscle, where it was reported to inhibit the folate–methionine cycle, raise levels of the AMPK activator AICAR and increase glucose uptake in muscle cells. In that paper, mice on a high-fat diet given MOTS-c gained less weight than untreated mice and handled glucose better, and the peptide was reported to improve insulin sensitivity in older mice.

A 2021 paper in Nature Communications added the exercise link: MOTS-c levels in muscle and plasma were reported to rise after a bout of exercise in a small group of healthy young men, and mice given the peptide late in life performed better on treadmill tests than untreated animals. The single-agent page is MOTS-c.

Nicotinamide N-methyltransferase consumes nicotinamide, the precursor of NAD+, and is reported to be upregulated in fat tissue and liver in obesity. A 2014 paper in Nature reported that knocking down NNMT in mice — with an antisense oligonucleotide, not a drug — protected them against diet-induced obesity and was associated with higher energy expenditure in fat cells.

5-Amino-1MQ is a small, membrane-permeable molecule designed to inhibit that enzyme inside the cell. A 2018 paper in Biochemical Pharmacology reported that diet-induced obese mice given the inhibitor for a short course had lower body weight, less white fat and smaller fat cells than untreated obese mice, without a change in food intake, alongside higher NAD+ in fat tissue. Everything known about it comes from mice and cultured cells; it has never been given to people in a published trial. The single-agent page is 5-Amino-1MQ.

Tesamorelin is a synthetic version of human growth-hormone-releasing hormone, modified to resist the enzyme that would otherwise degrade it within minutes. It binds the GHRH receptor on the pituitary and prompts a pulse of the patient's own growth hormone, acting downstream largely through liver-made IGF-1; because it works through the pituitary, normal feedback loops stay in place. Growth hormone promotes lipolysis, and visceral fat is particularly responsive to it, which is why the approved indication concerns visceral adipose tissue and why tesamorelin is the anchor of FUSION. A fuller treatment is on the tesamorelin page.

This is the clinical rationale for the blend — a rationale, not a finding.

This is the strongest area, and it belongs entirely to tesamorelin. Two phase 3 randomised, placebo-controlled trials in HIV-infected adults with abdominal fat accumulation are the basis of the approval. The first, in the New England Journal of Medicine in 2007, randomised 412 patients to tesamorelin 2 mg daily or placebo for 26 weeks and reported a reduction in visceral adipose tissue on CT of roughly 15 percent against a small increase on placebo, with IGF-1 rising as expected. A 2014 randomised trial in JAMA, in 50 HIV-infected patients, reported reductions in visceral fat and liver fat over six months against placebo. These are real human endpoints in a defined population — not the general population, not a compounded combination, and not the 0.75 mg per weekday dose in FUSION.

MOTS-c's evidence is preclinical: less weight gain and better glucose handling in high-fat-fed mice, and improved insulin sensitivity in aged mice. The human data is observational — levels reported to change with exercise and with age. No trial has given MOTS-c to people.

5-Amino-1MQ's evidence is the 2014 Nature knockdown study and the 2018 Biochemical Pharmacology inhibitor study, both in mice, plus cell work. The mouse findings are consistent and mechanistically coherent, and they are the whole of it.

BPC-157's original and largest literature is gastrointestinal protection in animal models; the tendon and soft-tissue work is also animal and cell research. Early-phase human work has been conducted for inflammatory bowel indications and there is substantial prescribing experience. Nothing in the BPC-157 literature concerns weight or metabolism directly.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of FUSION, or of any combination of these four components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is more uneven than in most blends:

• Tesamorelin has two phase 3 randomised placebo-controlled trials, all in HIV-infected adults with abdominal fat accumulation, and an FDA-approved product built on them. There are no randomised trials of tesamorelin for weight or body composition outside that population, and none of a compounded combination.
• MOTS-c has no human trials; its human evidence is observational measurement of the peptide's levels.
• 5-Amino-1MQ has no human trials of any kind.
• BPC-157 has early-phase human work for inflammatory bowel indications and substantial prescribing experience, but no large randomised controlled trials and none relevant to metabolism.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe FUSION on. But the accurate framing is "one component with human trials in a specific population, three described in preclinical research, all used clinically" — not "proven in people," and certainly not "proven for weight loss."

• That four agents together do more than any one alone. No study has compared the blend with its components.
• Any effect on body weight, waist size or body composition in the general population. Tesamorelin's endpoints were visceral adipose tissue on CT in HIV-infected adults; the other three have no human endpoints.
• An effect size or a timeline in humans for the blend. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety of the combination, which is part of why a physician reviews each refill and why bloodwork is usually required.
• Efficacy for any condition as an FDA-approved treatment. The one approved active in it is approved for a different population, at a different strength, as a different product.

Tesamorelin is the active ingredient in Egrifta, which the FDA first approved on 10 November 2010, and in its successors Egrifta SV and Egrifta WR, the current formulation, approved in March 2025. The approved indication is the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, at 1.28 mg once daily for Egrifta WR (2 mg once daily for Egrifta SV), and the label notes that long-term cardiovascular safety has not been established.

Compounded tesamorelin is a different thing. It is prepared by a licensed pharmacy against an individual prescription, here at a different strength and in combination with three other agents, and it is not FDA approved — the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Federal law also restricts compounding a drug that is essentially a copy of a commercially available product unless the prescriber determines the change produces a significant difference for the identified patient, which is one of the things the physician review is for.

Between 2023 and early 2026 both sat in Category 2 of the FDA's 503A bulk drug substances list, the category for substances flagged as presenting significant safety risks. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective about a week later, and BPC-157 and MOTS-c were both among them. The FDA's own Category 2 page, current as of 22 April 2026, now lists both only under withdrawn substances.

Removal from Category 2 lifts the safety-risk designation; it does not by itself place a substance on the positive 503A Bulks List. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding both to the 503A Bulks List — BPC-157 by 8 to 6 with one abstention, reviewed for ulcerative colitis, and MOTS-c by 7 to 5 with two abstentions, reviewed for obesity and osteoporosis. FDA's own reviewers had recommended against inclusion in each case, citing insufficient safety, efficacy and characterisation data; the committee voted the other way. A committee vote is a recommendation, not a decision. The FDA's own determination is still pending as of September 2026.

5-Amino-1MQ has never been through the same process. It does not appear on the FDA's Category 2 list, current as of 22 April 2026, and was not among the April removals because it was never there. It was not on the July 2026 advisory committee agenda, is not among the substances scheduled for the committee's next meeting before the end of February 2027, and is not on the 503A Bulks List. There is no FDA-approved product containing it. The accurate description is that the FDA has neither flagged it nor formally reviewed it.

One component is an approved active whose compounded form is not the approved product. Two are no longer restricted, have been recommended for the positive list by the advisory committee, and await final FDA action. One has no FDA file to speak of. None of the four, and not the blend, is an FDA-approved drug product, and compounded medications never are.

Most people notice little beyond injection-site tenderness. Tesamorelin's label lists fluid retention among its warnings, and prescribers describe some patients noticing mild puffiness in the hands or ankles or joint stiffness early on — usually a reason for an early check-in rather than a reason to stop. Noticing nothing at all is normal.

This is the window one vial covers. Prescribers most often describe subjective things here — sleep, morning energy, recovery from training — and, for those using FUSION alongside a GLP-1, less of the gut discomfort they associate with that medication. None of these has been tested in a trial.

The only human timeline for any component is tesamorelin's: the phase 3 trials measured visceral fat at 26 weeks, and the label tells prescribers to reconsider continuation in patients who have not had a reduction in visceral adipose tissue. Prescribers who use FUSION with waist measurement as the goal describe change, where it happens, as a two-to-three-month proposition alongside diet and training. This is where the physician typically wants a repeat IGF-1 and glucose panel.

There is no withdrawal described for any component. Tesamorelin works through the pituitary rather than replacing a hormone, so the axis is not suppressed when it stops; in the approved product's trials, visceral fat was reported to return toward baseline in patients who stopped, which is the honest answer to whether any benefit persists without it. For the other three, no human data exists either way.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split; you cannot take more of one and less of another. If your directions and syringe markings appear to disagree, ask before dosing.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. The approved tesamorelin products direct injection into the abdomen, avoiding the navel, scar tissue and bruises, and many prescribers carry that over to FUSION. Morning dosing is common. Your directions will say.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a monthly cycle. Weekends off is part of the schedule, not a missed dose. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating is on the label; a four-agent vial is not something to keep past it.

Both are built around tesamorelin and MOTS-c. PHYSIQ adds ipamorelin, a second growth-hormone secretagogue, and AOD-9604, a fragment of growth hormone studied for fat metabolism, so it is the more growth-hormone-axis-heavy formula. FUSION swaps those for 5-Amino-1MQ, which acts inside fat cells, and BPC-157, which is there for the gut.

SHRED has no tesamorelin. It pairs MOTS-c and AOD-9604 with CJC-1295 and ipamorelin, secretagogues acting on the same axis by a different route. FUSION is the one with the FDA-approved active in it. Neither has been studied as a blend.

Not competitors, and not in the same evidence class. Semaglutide and tirzepatide are GLP-1-based medications with large randomised trials for weight in the general population and FDA-approved counterparts for that use. FUSION has no human trial for weight at all. Patients commonly use FUSION alongside a GLP-1; the glucose interaction with tesamorelin is the thing the physician watches.

FUSION is supplied as a vial drawn with an insulin syringe. It is not currently available as a pepti Pen cartridge, a capsule or a nasal spray.